Eli Lilly Option Alert: Dec 19 $1000 Calls at the Ask: 100 vs 300 OI

Eli Lilly Option Alert: Dec 19 $1000 Calls at the Ask: 100 @ $69.0 vs 300 OI; Ref=$878.115

Eli Lilly Option Alert: Dec 19 $1000 Calls at the Bid: 400 vs 300 OI

Eli Lilly Option Alert: Dec 19 $1000 Calls at the Bid: 400 @ $69.0 vs 300 OI; Ref=$878.14

Eli Lilly Option Alert: Sep 19 $800 Puts Sweep (16) near the Bid: 137 vs 399 OI

Eli Lilly Option Alert: Sep 19 $800 Puts Sweep (16) near the Bid: 137 @ $47.497 vs 399 OI; Ref=$877.125

Eli Lilly Option Alert: Jun 20 $880 Puts at the Ask: 200 vs 1238 OI

Eli Lilly Option Alert: Jun 20 $880 Puts at the Ask: 200 @ $66.75 vs 1238 OI; Ref=$866.325

Eli Lilly Option Alert: Aug 15 $860 Calls at the Ask: 72 vs 174 OI

Eli Lilly Option Alert: Aug 15 $860 Calls at the Ask: 72 @ $88.5 vs 174 OI; Ref=$857.3088

Eli Lilly Option Alert: Jan, 2027 $450 Calls at the Ask: 20 vs 12 OI

Eli Lilly Option Alert: Jan, 2027 $450 Calls at the Ask: 20 @ $450.0 vs 12 OI; Ref=$859.68

Eli Lilly Option Alert: Feb 21 $740 Calls Sweep (9) near the Bid: 126 vs 508 OI

Eli Lilly Option Alert: Feb 21 $740 Calls Sweep (9) near the Bid: 126 @ $133.201 vs 508 OI; Ref=$873.16

Eli Lilly Option Alert: Apr 17 $920 Calls at the Ask: 400 vs 330 OI

Eli Lilly Option Alert: Apr 17 $920 Calls at the Ask: 400 @ $22.7 vs 330 OI; Ref=$871.955

Eli Lilly (NYSE:LLY) 株価情報

Eli Lilly

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly and Co

News

Upgrades

Pre-Market Outlook

Analyst Ratings

Trading Ideas

HOOD

TTWO

主要なアナリストが株式レーティングを見直したトピックスを紹介する。アナリストのレーティング変更（格上げ・格下げを含む）はアナリストレーティングのページをご覧いただきたい。

ロビンフッドのアナリスト　市場への評価を変更

Equities

Markets

ASTS

DXCM

TSLA

先週木曜日、主要な米国株指数は反発を推移した。ダウ平均は0.2%高の3万9935ドル、一方でS＆P500は0.5%安の5392ドルで取引を終了した。ナスダックは0.9%安の17182ドルで終了した。

米国株式市場　テスラが市場を牽引　NBA契約でディズニーも上昇

Short Sellers

Short Ideas

Eli Lilly and Co (NYSE:LLY) のフロートに対する新しいショート比率は、前回の報告から14.06％上昇しています。同社は最近、ショートで売られた株は616万株あり、これは取引可能なすべての普通株の0.73％に相当します。平均してこの株のショートポジションをカバーするには、トレーダーは2.39日かかります。

イーライリリー社をショート比率から分析

Liberty Media Corporation - Series A Liberty Live Common Stock

Liberty Live Group

LIBERTY LIVE SERIES B by Liberty Media Corporation

Liberty Media Corporation - Series C Liberty Live Common Stock

Tidal Trust II Defiance Daily Target 2X Long LLY ETF

Biotech

General

AMGN

DRIO

Hims & Hers Health, Inc. Class A Common Stock

HIMS

LFVN

RHHBY

TERN

VANI

VKTX

FDA Says Novo Nordisk's Ozempic Injection .68 mg/1 ml, Injection 1.34 mg/1 ml, Injection 2.68 Mg/1 ml Available As Of Feb 21; Novo Nordisk's Wegovy, Injection, 1.7 mg/.75 ml , Wegovy, Injection, 2.4 mg/.75 ml Now Available; FDA Says Semaglutide Injection Shortage Is Resolved As Of Feb 21

Investors with a lot of money to spend have taken a bullish stance on Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with LLY, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 46 uncommon options trades for Eli Lilly.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 39%, bearish.
Out of all of the special options we uncovered, 8 are puts, for a total amount of $378,149, and 38 are calls, for a total amount of $5,040,761.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $750.0 and $1080.0 for Eli Lilly, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Eli Lilly's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Eli Lilly's whale trades within a strike price range from $750.0 to $1080.0 in the last 30 days. 
<h3>Eli Lilly Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740079838_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/19/25</td>
<td>$70.15</td>
<td>$67.5</td>
<td>$69.0</td>
<td>$1000.00</td>
<td>$2.7M</td>
<td align="right">300</td>
<td align="right">1</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$70.0</td>
<td>$65.9</td>
<td>$69.0</td>
<td>$1000.00</td>
<td>$690.0K</td>
<td align="right">300</td>
<td align="right">401</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$135.8</td>
<td>$134.3</td>
<td>$135.8</td>
<td>$840.00</td>
<td>$162.9K</td>
<td align="right">142</td>
<td align="right">0</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/28/25</td>
<td>$12.0</td>
<td>$11.75</td>
<td>$12.0</td>
<td>$870.00</td>
<td>$97.2K</td>
<td align="right">98</td>
<td align="right">183</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$37.7</td>
<td>$36.85</td>
<td>$37.7</td>
<td>$880.00</td>
<td>$79.1K</td>
<td align="right">208</td>
<td align="right">28</td>
</tr>
</tbody>
</table>

<h3>About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Having examined the options trading patterns of Eli Lilly, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Eli Lilly</h3>
<ul>
<li>With a volume of 1,600,917, the price of LLY is up 0.69% at $873.03. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 70 days.</li>
</ul>
<h3>Professional Analyst Ratings for Eli Lilly</h3>
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $1066.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Overweight rating for Eli Lilly, targeting a price of $970. 
&#x2A; Maintaining their stance, an analyst from Truist Securities continues to hold a Buy rating for Eli Lilly, targeting a price of $1038. 
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Buy rating on Eli Lilly with a target price of $1190. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Eli Lilly options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Eli Lilly's Options Frenzy: What You Need to Know

Raw Materials and Product Supply
Most of the principal materials we use in our manufacturing operations are available from more than one source. However, certain materials are procured from a single source. We seek to maintain sufficient inventory to provide reliability of production and manage unforeseen supply variability. However, various developments have led, and may in the future lead, to interruption or shortages in supply until we establish new sources, implement alternative processes, bring new manufacturing facilities online, or pause or discontinue product sales in one or more markets.
Our active ingredient manufacturing and finishing operations, including formulation, filling, assembling, delivery device manufacturing, and packaging, take place at sites in the U.S., including Puerto Rico, Ireland and a number of other sites throughout the world. To support anticipated demand for our current and prospective products, we have undertaken significant manufacturing expansion initiatives. Investments to increase our manufacturing capacity include sites in North Carolina, Wisconsin, Ireland, Germany, and two in Indiana. We also utilize and are expanding arrangements with third parties for certain active ingredient manufacturing, filling, finishing operations, and for device or component production and assembly. Among these third parties, we, and the pharmaceutical industry generally, depend on China-based suppliers for portions of our supply chain. U.S. federal lawmakers are considering legislation that is intended to limit supply chain reliance on China, including the proposed BIOSECURE Act. In addition, historically, geopolitical tensions between the U.S. and China have led to the imposition of tariffs, sanctions, and certain other business restrictions between the U.S. and China. In February 2025, the U.S. presidential administration imposed new tariffs on China and China responded with tariffs on select U.S. goods. If new legislation or additional trade restrictions are adopted or geopolitical tensions were to increase and disrupt our operations in, or related to, China, such disruption could significantly impact our business and results of operations. See Item 1A, "Risk Factors—Risks Related to Our Operations—Reliance on third-party relationships and outsourcing arrangements could adversely affect our business" and "Risk Factors—Risks Related to Doing Business Internationally—Uneven economic growth or downturns or international trade and other global disruptions, geopolitical tensions, or disputes could adversely affect our business and operating results," for additional information.
We manage our supply chain (including our own facilities, contracted arrangements, and inventory) in a way that is intended to allow us to meet product demand while maintaining flexibility to reallocate manufacturing capacity to improve efficiency and respond to changes in supply and demand. To maintain supply of our products, we use a variety of techniques, including comprehensive quality systems, inventory management, and back-up sites.
However, pharmaceutical production processes are complex, highly regulated, and vary widely from product to product. Shifting or adding manufacturing capacity is a very lengthy process requiring significant capital expenditures, process modifications, and regulatory approvals. Accordingly, developments such as unanticipated demand, unplanned plant shutdowns, manufacturing or quality assurance difficulties at one of our facilities or contracted facilities, failure or refusal of a supplier or contract manufacturer to supply contracted quantities in a timely manner or at all, increases in demand on a supplier, or difficulties in predicting or variability in demand for and supply of our products and those of our competitors have led, and may in the future lead, to interruption or higher costs in the supply of certain products, product shortages, or pauses or discontinuations of product sales in one or more markets. For example, in periods of 2024, demand for our incretin medicines exceeded production. Supply and channel dynamics in some cases also contribute to variability in financial results for our products from period to period. Further, cost and wage inflation, availability of adequate capacity in global transportation, supply chain complexities, including consolidation therein, labor market issues, international tension and conflicts, uneven economic growth or downturns, an increase in overall demand in our industry for certain products and materials, and public health outbreaks, epidemics, or pandemics, have caused, and in the future may cause, delays or disruptions in and/or increased costs related to distribution of our medicines, the construction or acquisition of manufacturing capacity, procurement activity, and supplier or contract manufacturer arrangements, as well as other general business impacts. For more information on the additional risks we face in connection with any difficulties, disruptions, and shortages in the manufacturing, distribution, and sale of our products, see Item 1A, "Risk Factors—Risks Related to Our Business—Manufacturing, quality, or supply chain difficulties, disruptions, or shortages could lead to product supply problems."

Global

Eli Lilly Says If U.S. Governments New Trade Restrictions On China Are Adopted, It Could Impact Our Business And Results Of Operations

On Friday, the FDA approved Sanofi SA&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) Merilog as a biosimilar to Novo Nordisk A/S&#8216; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Novolog (insulin aspart) for improving glycemic control in adults and pediatric patients with diabetes mellitus.
Merilog, a rapid-acting human insulin analog, is the first rapid-acting insulin biosimilar product approved by the FDA.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43692253/sanofi-johnson-johnson-partnered-vaccine-against-bacterial-sepsis-flunks-late-stage-study" rel="noreferrer noopener">Sanofi/Johnson &amp; Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study</a>
As a rapid-acting insulin, Merilog helps lower mealtime blood sugar spikes and improve blood sugar control in people with diabetes. The <a target="_blank" href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-rapid-acting-insulin-biosimilar-product-treatment-diabetes" rel="noreferrer noopener">approval </a>is for a 3 milliliter (mL) single-patient-use prefilled pen and a 10 milliliter (mL) multiple-dose vial.
Merilog is the third insulin biosimilar product the FDA has approved, joining the two long-acting insulin biosimilar products the agency approved in 2021.
A biosimilar is a &#8220;biological product that is highly similar to, and has no clinically meaningful differences from, a biological product already approved by the FDA (also called the reference product).&#8221; The FDA has approved 65 biosimilar products to date.
Like Novolog, Merilog should be administered within five to ten minutes before the start of a meal. Merilog is administered subcutaneously (under the skin) by injection into the stomach, buttocks, thighs, or upper arms. Dosing of Merilog should be individualized and adjusted based on the patient&#8217;s needs.
Merilog may cause serious side effects, including hypoglycemia (low blood sugar), severe allergic reactions, and hypokalemia (low potassium in blood). Other common side effects may include injection site reactions, itching, rash, lipodystrophy (skin thickening or pitting at the injection site), weight gain, and swelling of hands and feet.
In 2023, Sanofi jumped the bandwagon with the other two insulin U.S. giants to&nbsp;lower the price of its best-selling insulin product, Lantus <a target="_blank" href="https://www.benzinga.com/general/biotech/23/03/31394427/three-is-company-sanofi-follows-lilly-novo-nordisk-slashes-insulin-product-price-by-78" rel="noreferrer noopener">(insulin glargine), by 78%</a>.
Sanofi said it would cap a&nbsp;Lantus patient&#8217;s monthly out-of-pocket cost at $35 for all patients with commercial insurance.&nbsp;
Also, in 2023, Sanofi acquired&nbsp;Provention Bio for $25.00 per share in cash, representing an equity value of <a target="_blank" href="https://www.benzinga.com/general/biotech/23/03/31318877/provention-bios-2-9b-acquisition-a-strategic-fit-for-sanofi" rel="noreferrer noopener">approximately $2.9 billion</a>.
The transaction adds a type 1 diabetes therapy to Sanofi&#8217;s core asset portfolio in General Medicines and further drives its strategic shift toward products with a differentiated profile.&nbsp;
In November, Doctors Without Borders/Médecins Sans Frontières highlighted that&nbsp;Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Novo Nordisk, and Sanofi, which dominate the global insulin market, have the power to set high&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41940958/humanitarian-organization-criticizes-eli-lilly-novo-nordisk-and-sanofi-of-having-double-standards-for-high-insulin-price" rel="noreferrer noopener">prices that restrict access</a>.
According to MSF, data published in&nbsp;JAMA Network Open&nbsp;shows that insulin pens could be produced for as little as $0.94 per unit and remain profitable, yet current prices far exceed this figure.
Price Action: SNY stock is down 0.59% at $54.18 during the premarket session on last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/02/43744606/analyst-cautiously-optimistic-on-dexcom-as-competitive-pressures-loom" target="_blank" rel="noreferrer noopener">Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom</a></li>
</ul>
Image by HJBC via Shutterstock

Large Cap

Health Care

FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes

Billionaire investor Stanley Druckenmiller&#8216;s family office Duquesne has divested his entire stake in Broadcom, simultaneously increasing his investments in major tech companies, as revealed in a recent 13-F filing.
What Happened: According to a recent&nbsp;SEC filing, Druckenmiller, a seasoned investor, sold all his shares of&nbsp;Broadcom Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) in the fourth quarter. This move comes on the heels of his total exit from Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), a competing chipmaker, a few months prior.
In the closing months of 2024, Druckenmiller significantly reduced his tech stock portfolio, selling his entire stakes in&nbsp;Microsoft Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>),&nbsp;Adobe Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) and&nbsp;Autodesk Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>). He also completely sold his stake in&nbsp;Starbucks Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) and his shares in insurance company&nbsp;Chubb Ltd.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>).
Despite these divestments, Druckenmiller increased his investments in several big tech companies in the same quarter, acquiring new positions in&nbsp;Alphabet Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>),&nbsp;Amazon.com Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), and Elon Musk&#8216;s electric vehicle manufacturer&nbsp;Tesla Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).
Druckenmiller&#8217;s Duquesne also initiated new investments in United Airlines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NYSE">UAL</a>), Delta Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>), Warner Bros. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NYSE">WBD</a>), Skechers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>), and Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
The most significant holding in his Duquesne Family Office remains Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), the clinical genetic-testing company in which they held a stake since 2022. Natera holdings account for just over 15% of the portfolio. Meanwhile, the firm increased its stake in Teva Pharmaceuticals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) by nearly 6.3 times. 
SEE ALSO: <a href="https://www.benzinga.com/25/02/43649046/warner-bros-jinjiang-international-collaborate-for-harry-potter-studio-tour-in-shanghai">Warner Bros Announces Shanghai Harry Potter Studio Tour—Set To Be Four Times Larger Than London&#8217;s</a>
Why It Matters: Druckenmiller, who formerly managed hedge funds for George Soros, now manages his own wealth through the Duquesne Family Office, which has investments worth nearly $3.72 billion.
The billionaire investor&#8217;s latest moves follow his earlier divestments in AI stocks. During the third quarter of 2024, <a href="https://www.benzinga.com/markets/equities/24/12/42668157/stanley-druckenmiller-dumps-streets-hottest-ai-stocks-heres-what-the-billionaire-investor-is-betting-on-next">Druckenmiller sold all of its Nvidia shares and significantly reduced its Palantir holdings</a> by 95%. This occurred despite Nvidia and Palantir experiencing significant stock surges that year, with Nvidia&#8217;s stock increasing nearly 190% and Palantir&#8217;s shares gaining over 386%. 
The current quarter&#8217;s exit from Broadcom despite the stock surging more than 100% over the past year appears as a profit booking move. Meanwhile, other additions in big tech stocks show his growing confidence in the sector.
Druckenmiller added Tesla to its portfolio which surged over 83% in the past year. However, the stock plunged more than 16% over the last month, amid declining global sales, regulatory roadblocks in China, earnings disappointment, and Musk&#8217;s increasing political involvement. 
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/25/02/43772576/tesla-to-start-delivering-shanghai-made-refreshed-model-ys-next-week">Tesla&#8217;s Refreshed Model Y Rolls Off Shanghai Gigafactory, Deliveries To Start &#8216;Soon&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Tech

ADBE

ADSK

AMZN

AVGO

GOOGL

MSFT

NTRA

NVDA

SBUX

TEVA

Billionaire Investor Stanley Druckenmiller Dumps Broadcom, Bets Big On Tesla, Amazon And Other Big Tech Stocks In Q4

<a href="https://www.benzinga.com/topic/ken-griffin">Ken Griffin</a>'s <a href="https://www.benzinga.com/topic/citadel-securities">hedge fund Citadel</a> has placed a £305 million ($390 million) short bet against GSK PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), marking the largest wager against the UK pharma giant in over a decade, <a href="https://www.ft.com/content/6520c6eb-4a30-4909-9c86-1b6b2e471743">reported</a> the Financial Times. 
The position, disclosed to the UK's Financial Conduct Authority, amounts to 0.51% of GSK's outstanding shares.
<h2 class="wp-block-heading">GSK's Rally Faces A Reality Check</h2>
GSK stock has climbed 8.20% in the past month, fueled by a £2 billion ($2.5 billion approx.) stock buyback and strong HIV and cancer drug sales. Yet, it still trails peers. 
Over the past five years, GSK shares have declined 17.53%, while the S&amp;P 500 pharmaceutical index has surged 45%. Griffin's short signals skepticism over the company's long-term pipeline, especially as its HIV drugs near a patent cliff.
Read Also: <a href="https://www.benzinga.com/general/biotech/25/02/43638136/goldman-sachs-turns-bearish-on-vaccine-maker-dynavax-amid-shingles-and-hepatitis-b-uncertainty">Goldman Sachs Turns Bearish On Vaccine Maker Dynavax Amid Shingles And Hepatitis B Uncertainty</a>
<h2 class="wp-block-heading">Hedge Funds, Analysts Are Split</h2>
This isn't the first time hedge funds have circled GSK. In 2021, activist investor Elliott Management pushed for a leadership shake-up. 
Meanwhile, JPMorgan analysts view GSK's latest earnings and guidance as "positive," but question the buyback's timing. Barclays called it "unexpected," while Jefferies deemed it "well received."
<h2 class="wp-block-heading">Takeaways For Investors</h2>
GSK's challenges have led to mixed bets on its future, but investors seeking exposure to Big Pharma without GSK's risks may look at industry leaders like Eli Lilly &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>). 
Alternatively, the iShares U.S. Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>) and SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>) provide diversified exposure.
With Citadel betting against GSK, the stock could see increased volatility—making it one to watch.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/02/43598644/deadly-bird-flu-strain-detected-in-nevada-man-4-stocks-to-watch">Deadly Bird Flu Strain Detected In Nevada Man: 4 Stocks To Watch</a></li>
</ul>
Image: Shutterstock

Hedge Funds

iShares Dow Jones US Pharmaceuticals Index Fund

Ken Griffin's Citadel Places Big Short Bet Against GSK - Here's What It Means for Investors

Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has outperformed the market over the past 15 years by 11.75% on an annualized basis producing an average annual return of 23.77%. Currently, Eli Lilly has a market capitalization of $759.92 billion. 
Buying $1000 In LLY: If an investor had bought $1000 of LLY stock 15 years ago, it would be worth $24,657.42 today based on a price of $845.00 for LLY at the time of writing.
<h3>Eli Lilly's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739570410_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

Soros Fund Management Reports Share Stake Of 33,600 Shares In Eli Lilly

AAPL

ACHC

CBRE

WDAY

Viking Global Investors' Latest 13F Filing Reveals Dissolved Stakes In Apple By 4.86M Shares, Workday By 3.27M Shares, Las Vegas Sands By 8.67M Shares, McDonald's By 1.12M Shares, Vertiv Holdings By 2.81M Shares, Acadia Healthcare By 3.70M Shares, CBRE Group By 1.57M Shares, Carnival By 9.56M Shares, Freeport-McMoRan By 3.14M Shares, Eli Lilly By 152K Shares, 3M By 840.75K Shares, Ameriprise Financial By 243.06K Shares, Tesla By 436.27K Shares, Rogers Communications By 2.70M Shares

<a href="https://www.sec.gov/Archives/edgar/data/1167483/000091957425001475/xslForm13F_X02/infotable.xml">https://www.sec.gov/Archives/edgar/data/1167483/000091957425001475/xslForm13F_X02/infotable.xml</a>

AMAT

CPNG

RDDT

SPOT

UBER

Tiger Global Management's Latest 13F Filing Shows Increased Positions In Eli Lilly By 1.31M Shares, Reddit By 2.03M Shares, Coupang By 8.12M Shares, Sherwin-Williams By 1.00M Shares, Spotify By 1.26M Shares; Decreased Holdings In UnitedHealth By 438.8K Shares, Nu Holdings By 8.88M Shares, Uber Technologies By 2.60M Shares, Applied Materials By 895.2K Shares, Novo Nordisk By 1.27M Shares

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$27.50</td>
<td>$48.6K</td>
<td>44.4K</td>
<td>7.2K</td>
</tr>
<tr>
<td>ACAD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$20.00</td>
<td>$157.6K</td>
<td>109</td>
<td>1.9K</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$65.00</td>
<td>$28.5K</td>
<td>2.8K</td>
<td>840</td>
</tr>
<tr>
<td>ZTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$180.00</td>
<td>$43.0K</td>
<td>1.4K</td>
<td>316</td>
</tr>
<tr>
<td>EBS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$11.00</td>
<td>$43.8K</td>
<td>4</td>
<td>200</td>
</tr>
<tr>
<td>BMRN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$65.00</td>
<td>$29.2K</td>
<td>1.3K</td>
<td>159</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$245.00</td>
<td>$191.7K</td>
<td>141</td>
<td>125</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$37.00</td>
<td>$69.7K</td>
<td>1.0K</td>
<td>87</td>
</tr>
<tr>
<td>EXEL</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$17.00</td>
<td>$29.5K</td>
<td>98</td>
<td>50</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$800.00</td>
<td>$37.5K</td>
<td>843</td>
<td>31</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we notice a call option sweep that happens to be bullish, expiring in 37 day(s) on March 21, 2025. This event was a transfer of 2561 contract(s) at a $27.50 strike. This particular call needed to be split into 21 different trades to become filled. The total cost received by the writing party (or parties) was $48.6K, with a price of $19.0 per contract. There were 44426 open contracts at this strike prior to today, and today 7236 contract(s) were bought and sold. 
• For ACAD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>), we notice a call option sweep that happens to be bullish, expiring in 128 day(s) on June 20, 2025. This event was a transfer of 901 contract(s) at a $20.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $157.6K, with a price of $175.0 per contract. There were 109 open contracts at this strike prior to today, and today 1920 contract(s) were bought and sold. 
• For TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we notice a call option trade that happens to be bearish, expiring in 64 day(s) on April 17, 2025. This event was a transfer of 20 contract(s) at a $65.00 strike. The total cost received by the writing party (or parties) was $28.5K, with a price of $1425.0 per contract. There were 2849 open contracts at this strike prior to today, and today 840 contract(s) were bought and sold. 
• For ZTS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>), we notice a call option sweep that happens to be bearish, expiring in 9 day(s) on February 21, 2025. This event was a transfer of 200 contract(s) at a $180.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $43.0K, with a price of $215.0 per contract. There were 1473 open contracts at this strike prior to today, and today 316 contract(s) were bought and sold. 
• Regarding EBS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>), we observe a call option trade with bearish sentiment. It expires in 219 day(s) on September 19, 2025. Parties traded 200 contract(s) at a $11.00 strike. The total cost received by the writing party (or parties) was $43.8K, with a price of $219.0 per contract. There were 4 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• Regarding BMRN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>), we observe a call option trade with bullish sentiment. It expires in 9 day(s) on February 21, 2025. Parties traded 150 contract(s) at a $65.00 strike. The total cost received by the writing party (or parties) was $29.2K, with a price of $195.0 per contract. There were 1333 open contracts at this strike prior to today, and today 159 contract(s) were bought and sold. 
• For HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we notice a call option trade that happens to be bearish, expiring in 64 day(s) on April 17, 2025. This event was a transfer of 65 contract(s) at a $245.00 strike. The total cost received by the writing party (or parties) was $191.7K, with a price of $2950.0 per contract. There were 141 open contracts at this strike prior to today, and today 125 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a call option trade that happens to be bullish, expiring in 9 day(s) on February 21, 2025. This event was a transfer of 81 contract(s) at a $37.00 strike. The total cost received by the writing party (or parties) was $69.7K, with a price of $861.0 per contract. There were 1026 open contracts at this strike prior to today, and today 87 contract(s) were bought and sold. 
• For EXEL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>), we notice a call option trade that happens to be neutral, expiring in 9 day(s) on February 21, 2025. This event was a transfer of 18 contract(s) at a $17.00 strike. The total cost received by the writing party (or parties) was $29.5K, with a price of $1640.0 per contract. There were 98 open contracts at this strike prior to today, and today 50 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option trade with bearish sentiment. It expires in 9 day(s) on February 21, 2025. Parties traded 5 contract(s) at a $800.00 strike. The total cost received by the writing party (or parties) was $37.5K, with a price of $7518.0 per contract. There were 843 open contracts at this strike prior to today, and today 31 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACAD

BMRN

EXEL

10 Health Care Stocks With Whale Alerts In Today's Session

Investors with a lot of money to spend have taken a bearish stance on Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with LLY, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 36 uncommon options trades for Eli Lilly.
This isn't normal.
The overall sentiment of these big-money traders is split between 41% bullish and 44%, bearish.
Out of all of the special options we uncovered, 10 are puts, for a total amount of $468,617, and 26 are calls, for a total amount of $1,742,517.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $500.0 to $1040.0 for Eli Lilly over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Eli Lilly stands at 484.97, with a total volume reaching 1,651.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Eli Lilly, situated within the strike price corridor from $500.0 to $1040.0, throughout the last 30 days.
<h3>Eli Lilly Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739380523_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$42.75</td>
<td>$42.7</td>
<td>$42.75</td>
<td>$960.00</td>
<td>$384.7K</td>
<td>67</td>
<td align="right">102</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/07/25</td>
<td>$23.7</td>
<td>$22.45</td>
<td>$22.45</td>
<td>$875.00</td>
<td>$134.7K</td>
<td>18</td>
<td align="right">66</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$109.95</td>
<td>$109.0</td>
<td>$109.0</td>
<td>$900.00</td>
<td>$109.0K</td>
<td>1.0K</td>
<td align="right">11</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/07/25</td>
<td>$20.65</td>
<td>$19.75</td>
<td>$20.65</td>
<td>$875.00</td>
<td>$103.2K</td>
<td>18</td>
<td align="right">116</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$115.3</td>
<td>$113.55</td>
<td>$115.3</td>
<td>$840.00</td>
<td>$92.2K</td>
<td>145</td>
<td align="right">8</td>
</tr>
</tbody>
</table>

<h3>About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
After a thorough review of the options trading surrounding Eli Lilly, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Eli Lilly Standing Right Now?</h3>
<ul>
<li>With a trading volume of 1,031,908, the price of LLY is up by 1.05%, reaching $874.11.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 78 days from now.</li>
</ul>
<h3>Expert Opinions on Eli Lilly</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $1066.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Overweight rating for Eli Lilly, targeting a price of $970. 
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on Eli Lilly, which currently sits at a price target of $1190. 
&#x2A; An analyst from Truist Securities has decided to maintain their Buy rating on Eli Lilly, which currently sits at a price target of $1038. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Eli Lilly with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Behind the Scenes of Eli Lilly's Latest Options Trends

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/14/25</td>
<td>$75.00</td>
<td>$39.4K</td>
<td>2.1K</td>
<td>8.1K</td>
</tr>
<tr>
<td>AHCO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$10.00</td>
<td>$71.4K</td>
<td>0</td>
<td>4.7K</td>
</tr>
<tr>
<td>THC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$145.00</td>
<td>$105.8K</td>
<td>1.1K</td>
<td>1.0K</td>
</tr>
<tr>
<td>COR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$230.00</td>
<td>$822.5K</td>
<td>495</td>
<td>258</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$35.00</td>
<td>$81.1K</td>
<td>5.1K</td>
<td>217</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$270.00</td>
<td>$140.0K</td>
<td>355</td>
<td>200</td>
</tr>
<tr>
<td>SYK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$390.00</td>
<td>$39.6K</td>
<td>484</td>
<td>151</td>
</tr>
<tr>
<td>MCK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/28/25</td>
<td>$610.00</td>
<td>$53.0K</td>
<td>100</td>
<td>137</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$67.50</td>
<td>$33.6K</td>
<td>1.8K</td>
<td>120</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$860.00</td>
<td>$25.3K</td>
<td>50</td>
<td>112</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we notice a call option trade that happens to be bearish, expiring in 3 day(s) on February 14, 2025. This event was a transfer of 200 contract(s) at a $75.00 strike. The total cost received by the writing party (or parties) was $39.4K, with a price of $197.0 per contract. There were 2192 open contracts at this strike prior to today, and today 8123 contract(s) were bought and sold. 
• Regarding AHCO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHCO#NASDAQ">AHCO</a>), we observe a put option sweep with bearish sentiment. It expires in 220 day(s) on September 19, 2025. Parties traded 476 contract(s) at a $10.00 strike. This particular put needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $71.4K, with a price of $150.0 per contract. There were 0 open contracts at this strike prior to today, and today 4752 contract(s) were bought and sold. 
• For THC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>), we notice a call option sweep that happens to be neutral, expiring in 10 day(s) on February 21, 2025. This event was a transfer of 300 contract(s) at a $145.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $105.8K, with a price of $355.0 per contract. There were 1108 open contracts at this strike prior to today, and today 1040 contract(s) were bought and sold. 
• Regarding COR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>), we observe a call option trade with bearish sentiment. It expires in 339 day(s) on January 16, 2026. Parties traded 250 contract(s) at a $230.00 strike. The total cost received by the writing party (or parties) was $822.5K, with a price of $3290.0 per contract. There were 495 open contracts at this strike prior to today, and today 258 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a call option sweep with bullish sentiment. It expires in 339 day(s) on January 16, 2026. Parties traded 100 contract(s) at a $35.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $81.1K, with a price of $812.0 per contract. There were 5109 open contracts at this strike prior to today, and today 217 contract(s) were bought and sold. 
• For AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we notice a put option trade that happens to be bullish, expiring in 129 day(s) on June 20, 2025. This event was a transfer of 200 contract(s) at a $270.00 strike. The total cost received by the writing party (or parties) was $140.0K, with a price of $700.0 per contract. There were 355 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• For SYK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), we notice a put option sweep that happens to be bearish, expiring in 10 day(s) on February 21, 2025. This event was a transfer of 99 contract(s) at a $390.00 strike. This particular put needed to be split into 23 different trades to become filled. The total cost received by the writing party (or parties) was $39.6K, with a price of $400.0 per contract. There were 484 open contracts at this strike prior to today, and today 151 contract(s) were bought and sold. 
• For MCK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), we notice a call option sweep that happens to be bullish, expiring in 17 day(s) on February 28, 2025. This event was a transfer of 53 contract(s) at a $610.00 strike. This particular call needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $53.0K, with a price of $1000.0 per contract. There were 100 open contracts at this strike prior to today, and today 137 contract(s) were bought and sold. 
• Regarding AZN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), we observe a call option sweep with bearish sentiment. It expires in 65 day(s) on April 17, 2025. Parties traded 57 contract(s) at a $67.50 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $33.6K, with a price of $590.0 per contract. There were 1841 open contracts at this strike prior to today, and today 120 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a put option trade that happens to be bearish, expiring in 157 day(s) on July 18, 2025. This event was a transfer of 4 contract(s) at a $860.00 strike. The total cost received by the writing party (or parties) was $25.3K, with a price of $6340.0 per contract. There were 50 open contracts at this strike prior to today, and today 112 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AHCO

MRNA

On Monday, Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) inked two strategic collaborations to expand radiopharmaceuticals and metabolic-associated steatohepatitis (MASH), respectively.
AdvanCell <a target="_blank" href="https://www.businesswire.com/news/home/20250210990350/en/AdvanCell-Enters-Into-Strategic-Collaboration-with-Lilly-to-Advance-Novel-Targeted-Alpha-Therapies-for-the-Treatment-of-Cancer" rel="noreferrer noopener">announced</a> that it is expanding the scope and breadth of its strategic collaboration with Eli Lilly to research and develop cancer treatments.
Under this new agreement, the parties will leverage AdvanCell's proprietary Pb-212 production technology, radionuclide development infrastructure, and Lilly's drug candidate programs to facilitate the development and accelerate the clinical advancement of an expanded portfolio of targeted alpha therapies.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43558004/eli-lillys-recently-approved-inflammatory-bowel-disease-drug-shows-sustained-and-durable-treatment-at-two-years" rel="noreferrer noopener">Eli Lilly's Recently Approved Inflammatory Bowel Disease Drug Shows Sustained And Durable Treatment At Two Years</a>
In 2023, Eli Lilly acquired&nbsp;POINT Biopharma Global&nbsp;at $12.50 per share in cash, an aggregate of&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/10/35060421/why-is-cancer-treatment-focused-point-biopharma-stock-trading-higher-today" rel="noreferrer noopener">approximately $1.4 billion</a>.
In June 2023, POINT Biopharma and AdvanCell <a target="_blank" href="https://www.globenewswire.com/news-release/2023/06/26/2694358/0/en/POINT-Biopharma-and-AdvanCell-to-Collaborate-in-the-Development-of-Lead-212-Labeled-Radioligands.html" rel="noreferrer noopener">collaborated</a> on developing a global&nbsp;212Pb radioisotope and radioligand supply chain and drug manufacturing network for&nbsp;212Pb-labeled radioligands by each company.
Financial terms of the agreement were not disclosed.
Concurrently, Korea-based OliX Pharmaceuticals Inc. announced a global licensing agreement with Eli Lilly for the development and commercialization of OliX's OLX75016, a Phase 1 candidate primarily targeting metabolic-associated steatohepatitis (MASH) and other cardiometabolic indications.
OliX will <a target="_blank" href="https://www.businesswire.com/news/home/20250210958713/en/OliX-and-Lilly-Enter-Global-Licensing-Agreement-for-MASH-and-Other-Cardiometabolic-Indications" rel="noreferrer noopener">receive</a> an initial payment from Lilly to complete the Phase 1 clinical trial underway in Australia.
In preclinical studies, OliX has demonstrated the efficacy of OLX75016 in addressing MASH, liver fibrosis, and other cardiometabolic indications.
Recently, Eli Lilly reported fourth-quarter revenue of $13.53 billion, up 45% year over year, almost in line with the&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43525518/eli-lilly-q4-earnings-strong-demand-for-mounjaro-but-prices-dip-forecasts-over-30-jump-in-2025-sales-on-newer-medicines" rel="noreferrer noopener">consensus of $13.57 billion</a>.
The increase was driven by a 48% increase in volume, partially offset by a 4% decrease due to lower realized prices.
Price Action: LLY stock is down 1.40% at $865.99 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43597552/whats-going-on-with-cisco-systems-stock-today" target="_blank" rel="noreferrer noopener">Cisco Unveils First Jointly Developed AI Agent From Mistral AI Partnership &#8211; What's On The Cards?</a></li>
</ul>
Photo via Shutterstock

Contracts

Eli Lilly Seeks To Expand Into Cancer Radiopharma And Fatty Liver, With Two Global Deals

Last week was <a href="https://www.benzinga.com/25/02/43574339/magnificent-seven-slip-inflation-fears-grip-consumers-gold-hits-record-highs">another power-packed one</a>. Wall Street faced volatility as tech earnings disappointed, labor data signaled mixed trends, and inflation fears grew amid rising tariffs. Gold hit record highs as a safe haven, while geopolitical tensions and Ford's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) weak EV outlook added to market uncertainty. Amid these dynamics, we identified <a href="https://www.benzinga.com/etfs">five ETFs </a>that braved the volatility and posted gains:
Direxion Daily PLTR Bull 2X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTU#NASDAQ">PLTU</a>)
<ul>
<li>Weekly gain:&nbsp;78.82%</li>
<li>Focus: Leveraged equity ETF that seeks to track 200% of the performance of Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>).</li>
<li>Expense ratio:&nbsp;0.99%</li>
</ul>
AdvisorShares Psychedelics ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSIL#NYSE">PSIL</a>)
<ul>
<li>Weekly gain:&nbsp;21.61%</li>
<li>Focus:&nbsp;Primarily invests in life sciences companies focused on psychedelic medicines as well as other companies with business in the psychedelics space. </li>
<li>Expense ratio:&nbsp;1.01%</li>
</ul>
United States Natural Gas Fund LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNG#NYSE">UNG</a>)
<ul>
<li>Weekly gain:&nbsp;10.84%</li>
<li>Focus:&nbsp;Tracks the daily price movements of natural gas. This ETF mainly invests in natural gas futures contracts.</li>
<li>Expense ratio:&nbsp;1.01%</li>
</ul>
Roundhill Video Games ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NERD#NASDAQ">NERD</a>) 
<ul>
<li>Weekly gain:&nbsp;4.75%</li>
<li>Focus:&nbsp;Follows the Nasdaq CTA Global Video Games Software Index. Names like Nintendo, Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) and Take-Two Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) are included in this passively managed ETF&#8217;s portfolio.</li>
<li>Expense ratio:&nbsp;0.50%</li>
</ul>
Defiance Connective Technologies ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIXG#NASDAQ">SIXG</a>)
<ul>
<li>Weekly gain:&nbsp;4.58%</li>
<li>Focus: Tracks the BlueStar Connective Technologies Index that follows the performance of U.S.-listed companies in the hardware, software, or services related to 5G, or 6G networks, and other connective technologies.</li>
<li>Expense ratio:&nbsp;0.30%</li>
</ul>
Also Read: <a href="https://www.benzinga.com/trading-ideas/movers/25/02/43594031/t-mobile-stock-is-rising-monday-whats-going-on">T-Mobile Stock Is Rising Monday: What&#8217;s Going On?</a>
What Drove Markets Last Week
Beginning with the mega-cap tech earnings last week, companies including Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) and Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), fell short of lofty expectations, weighing on markets despite support from Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and financial sector stocks. 
On the economic front, January's job report was a mixed bag. Nonfarm payrolls rose just 143,000—far below December's 307,000 and short of economists' 170,000 estimate. Yet, the unemployment rate dipped, and wages climbed faster than expected.
A warning sign popped up Friday when the University of Michigan's consumer sentiment index unexpectedly dropped. The survey showed consumer sentiment falling to 67.8, with inflation expectations rising to 4.3%—the highest since late 2023. The report linked this unease to higher tariffs under the Trump administration.
Gold surged to record highs, topping $2,850 per ounce, as investors sought safety amid inflation worries and policy uncertainty. This marks its sixth straight week of gains, reinforcing its safe-haven status.
Meanwhile, Ford's stock slid to its lowest level since early 2021 despite an earnings beat. Its weak 2025 outlook and projected $5 billion to $5.5 billion EV losses raised fresh concerns about profitability and competition in the electric vehicle market.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/asia/25/02/43573186/china-tech-etfs-surge-as-deepseek-led-ai-boom-fuels-bull-market">China Tech ETFs Surge As DeepSeek-Led AI Boom Fuels Bull Market</a></li>
</ul>
Photo: Shutterstock

Broad U.S. Equity ETFs

ETFs

NERD

PLTR

PLTU

PSIL

RBLX

SIXG

5 ETFs That Beat Market Turmoil With Gains Last Week

Eli Lilly Files for Six-Part Notes Offering; Size Not Disclosed

<a href="https://www.businesswire.com/news/home/20250210958713/en/" title="https://www.businesswire.com/news/home/20250210958713/en/">https://www.businesswire.com/news/home/20250210958713/en/</a>
<a href="https://www.businesswire.com/news/home/20250210958713/en/" title="https://www.businesswire.com/news/home/20250210958713/en/">https://www.businesswire.com/news/home/20250210958713/en/</a>

Olix And Eli Lilly Enter Into A Global Licensing Agreement, Focused On The Development And Commercialization Of Olix's OLX75016

It's been a cautious week on Wall Street as earnings from mega-cap tech companies prompted investors to reassess their high expectations for future growth.
Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) and Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) were the latest among Magnificent Seven stocks to fall short of lofty guidance forecasts, weighing on the broader market. Drugmaker Eli Lilly Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and financial stocks provided a cushion, helping offset some of the <a href="https://www.benzinga.com/markets">weakness in mega-cap tech.</a>
On the macroeconomic front, January&#8217;s labor market data sent mixed signals. Nonfarm payrolls rose by 143,000, a sharp slowdown from December's 307,000 and well below economist forecasts of 170,000. Yet the unemployment rate edged lower and wages grew at <a href="https://www.benzinga.com/economics/macro-economic-events/25/02/43559446/us-economy-adds-fewer-than-expected-jobs-in-january-unemployment-slows-wage-growth-spikes">a faster-than-expected pace.</a>
A warning sign emerged Friday when the University of Michigan's consumer sentiment index revealed an unexpected decline in February, with the report highlighting an "unusually large" increase in year-ahead inflation expectations. The survey attributed much of this anxiety to higher tariffs under the <a href="https://www.benzinga.com/topic/donald-trump">Trump administration.</a>
Gold, as tracked by the SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>), surged to new all-time highs as investors sought protection against inflation and policy uncertainty. The precious metal repeatedly broke above $2,850 per ounce, marking its sixth consecutive week of gains and reinforcing its status as the go-to safe-haven asset <a href="https://www.benzinga.com/economics/macro-economic-events/25/02/43512109/gold-extends-records-as-central-banks-rush-to-buy-bullion-miners-eye-sixth-straight-winning-week">amid an environment of economic risks</a>.
Geopolitical developments also shaped market sentiment. During a meeting with Israeli Prime Minister Benjamin Netanyahu, Trump outlined a new vision for Gaza, suggesting the United States could &#8220;take over&#8221; and transform it into the "Riviera of the Middle East" while relocating Palestinians <a href="https://www.benzinga.com/news/25/02/43503385/trumps-gaza-plan-for-seaside-resort-faces-global-pushback">to Jordan and Egypt.</a>
The U.S. Treasury announced fresh measures aimed at sanctioning Iran's oil export network to China as part of Washington's broader strategy to exert &#8220;maximum economic pressure&#8221; and prevent Iran from <a href="https://www.benzinga.com/government/regulations/25/02/43540757/oil-prices-trim-losses-as-department-of-treasury-issues-sanctions-on-irans-crude-shipments-to-china">advancing its nuclear program.</a>
On Friday, Trump hinted at plans to announce reciprocal tariffs as early as next week. 
<h3 class="wp-block-heading">Ford's Outlook Disappoints</h3>
Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>)&#8217;s fourth-quarter earnings beat expectations, but its weak 2025 outlook and projected $5 billion-$5.5 billion losses in the electric vehicle segment sent the stock to the lowest level since January 2021. Analysts remain cautious, citing profitability concerns and competitive pressures <a href="https://www.benzinga.com/25/02/43540794/what-analysts-are-saying-about-fords-q4-performance-and-outlook">in the EV market.</a>
<h3 class="wp-block-heading">Inflation Expectations Spike</h3>
U.S. consumer sentiment fell to 67.8 in February, per the University of Michigan survey, missing forecasts. Inflation expectations rose to 4.3%, the <a href="https://www.benzinga.com/25/02/43564020/consumer-sentiment-sinks-economist-flags-unusually-large-rise-in-inflation-perception">highest since November 2023.</a>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/02/43544975/banks-win-first-regulatory-relief-as-fed-softens-stress-test-rules-scraps-climate-risks-financial-stocks-hit-record-highs">Fed Eases Bank Stress Tests, Drops Climate Risks: Financial Stocks Hit Record Highs</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Earnings Beats

Commodities

Econ #s

GOOG

Magnificent Seven Slip, Inflation Fears Grip Consumers, Gold Hits Record Highs: This Week In The Markets

Eli Lilly's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) short percent of float has risen 25.0% since its last report. The company recently reported that it has 7.22 million shares sold short, which is 0.9% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.69 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Eli Lilly Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738954828_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Eli Lilly has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Eli Lilly's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Eli Lilly's peer group average for short interest as a percentage of float is 4.12%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Eli Lilly's Recent Short Interest

On Friday, Eli Lilly And Cao (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) announced the results from the VIVID-2 open-label extension study of Omvoh&nbsp;(mirikizumab-mrkz).
In January, the FDA approved&nbsp;Omvoh for moderately to severely active Crohn's&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43053632/fda-approves-expanded-use-of-eli-lillys-ulcerative-colitis-drug-for-crohns-disease" rel="noreferrer noopener">disease in adults</a>.
Omvoh is now approved in the U.S. for two types of inflammatory bowel disease (IBD), following its&nbsp;October 2023&nbsp;approval as a first-in-class treatment for moderately to severely active ulcerative colitis (UC) in adults.
The trial showed that most patients with moderately to severely active Crohn's disease received two years of continuous treatment with Omvoh and achieved long-term clinical and endoscopic outcomes, including those (43.8%) with previous biologic failure.
<ul>
<li>Among patients in clinical remission at one year in VIVID-1, 92.9% maintained clinical remission at two years.</li>
<li>Among patients treated in VIVID-2, 87.6% maintained endoscopic response, defined by visible healing of the intestinal lining.</li>
<li>Among patients in endoscopic remission at one year of treatment in VIVID-1, 78.6% maintained endoscopic remission at two years.</li>
</ul>
Additionally:
<ul>
<li>Among patients not in clinical remission at one year, 60.8% gained clinical remission during the second year of treatment.</li>
<li>Among patients not in endoscopic remission at one year, 35.4% gained endoscopic remission during the second year of treatment.</li>
</ul>
In VIVID-2, Omvoh's long-term safety profile in patients with moderately to severely active Crohn's disease was generally consistent with its known safety profile.
In October, Eli Lilly announced data from a VIVID-1 Phase 3 study that evaluated the safety and efficacy of mirikizumab compared with a placebo and active control (Johnson &amp; Johnson's&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jnj#NYSE">JNJ</a>) Stelara (ustekinumab)) in adults with moderately to severely&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41314649/more-patients-on-eli-lillys-mirikizumab-achieved-histologic-response-at-one-year-compared-to-john" rel="noreferrer noopener">active Crohn's disease</a>.&nbsp;
The data showed that more patients who achieved&nbsp;histologic response were observed with mirikizumab at Week 52 in the overall population (58.2% versus 48.8%; p=0.0075).
Data from two Phase 3 studies of mirikizumab across two types of&nbsp;inflammatory bowel diseases showed patients treated with mirikizumab sustained stable, long-term remission in ulcerative colitis <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41580394/eli-lillys-mirikizumab-shows-long-term-sustained-efficacy-safety-for-ulcerative-colitis-and-crohn" rel="noreferrer noopener">and Crohn's disease</a>.
Price Action: LLY stock is up 0.20% at $872.14 during the premarket session on last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/25/02/43555852/jeep-maker-stellantis-expands-ai-push-with-mistral-ai-partnership-details" target="_blank" rel="noreferrer noopener">Jeep Maker Stellantis Expands AI Push With Mistral AI Partnership: Details</a></li>
</ul>
Photo by Jonathan Weiss via Shutterstock

Eli Lilly's Recently Approved Inflammatory Bowel Disease Drug Shows Sustained And Durable Treatment At Two Years

Press Releases

Indiana Sees $39 Billion Worth of Projects Under Construction, an Industrial Info News Alert

FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity

Lilly to participate in J.P. Morgan Healthcare Conference

Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program

Earnings

Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidance

FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease

Lilly confirms date and conference call for fourth-quarter 2024 financial results and 2025 financial guidance announcement

Lilly reports full Q4 2024 financial results and provides 2025 guidance

Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years

Lilly to participate in TD Cowen's 45th Annual Health Care Conference

STLA

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Comments

Eli Lilly

Unusual Options Activity for

ニュース

パートナーシップ

ベンジンガ・グローバル

Date	Put/Call	Strike Price	Exp Date	DTE	Trade Vol	Day Vol	Vol / OI	OI	Trade Type	Sentiment
10:32 AMFeb 20, 2025	CALL	$1000.00	Dec 19, 2025	299	401	100	134	300	TRADE	BULLISH
10:30 AMFeb 20, 2025	CALL	$1000.00	Dec 19, 2025	299	1	400	0	300	TRADE	NEUTRAL
11:27 AMFeb 19, 2025	PUT	$800.00	Sep 19, 2025	208	138	137	35	399	SWEEP	BULLISH
10:29 AMFeb 19, 2025	PUT	$880.00	Jun 20, 2025	117	201	200	16	1238	TRADE	BEARISH
02:52 PMFeb 18, 2025	CALL	$860.00	Aug 15, 2025	173	633	72	364	174	TRADE	BULLISH
10:04 AMFeb 18, 2025	CALL	$450.00	Jan 15, 2027	691	0	20	0	12	TRADE	BULLISH
02:36 PMFeb 13, 2025	CALL	$740.00	Feb 21, 2025	-2	421	126	83	508	SWEEP	BEARISH
01:08 PMFeb 13, 2025	CALL	$920.00	Apr 17, 2025	53	400	400	121	330	TRADE	BULLISH